Continuous Positive Airway Pressure Ventilation After Acute Ischemic Stroke

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00151177
Recruitment Status : Completed
First Posted : September 8, 2005
Last Update Posted : November 24, 2010
New Health Sciences, Inc.
Rubel GmbH, Heiligenhaus, Germany
Information provided by:
University Hospital Muenster

September 7, 2005
September 8, 2005
November 24, 2010
April 2005
January 2008   (Final data collection date for primary outcome measure)
Primary endpoint is to test the feasibility of early non-invasive CPAP ventilation in acute stroke patients
Same as current
Complete list of historical versions of study NCT00151177 on Archive Site
  • Size of brain infarction on diffusion weighted MRI imaging at day 10 after symptom onset
  • Disability measured by the modified Rankin scale after three months
Same as current
Not Provided
Not Provided
Continuous Positive Airway Pressure Ventilation After Acute Ischemic Stroke
Feasibility and Efficacy Study of Early Continuous Positive Airway Pressure Ventilation in Patients With Acute Ischemic Stroke

More than half of all stroke patients have sleep apneas in the acute phase after stroke. Sleep apneas may be associated with higher degrees of disability three months after stroke due to numerous factors associated with sleep apneas such as persistent hypertension, cardiac arrhythmias, and clotting disorders.

Non-invasive CPAP (continuous positive airway pressure)-therapy may reverse a number of these effects very shortly after initiation. The aim of the study is to test the feasibility of early non-invasive CPAP treatment starting in the first night after stroke onset, and to test its efficacy in a randomized clinical trial.

50 patients with acute ischemic stroke will be enrolled and randomly assigned to standard care PLUS CPAP treatment or standard care only. All patients randomized to the intervention group will receive CPAP therapy for the first three nights after stroke. In the fourth night, a cardiorespiratory polygraphy will be performed in patients and controls. Patients assigned to the intervention group with a respiratory distress index > 10/h will be treated further on. On admission, day 4, and day 10 after stroke, diffusion weighted MRI imaging will be performed to determine the size of the infarction. The NIHSS score will be used to assess clinical short-term outcome on day 4 and day 10. After three months, the outcome will be determined using the modified Rankin scale.

As CPAP therapy may be more laborious for the provider, the additional work-load will be documented using pre-specified scales.

Primary hypothesis of the study is, that CPAP therapy is feasible in acute stroke patients and that the additional work load will not outweigh the benefits.

Secondary hypothesis is that patients assigned to the treatment group have smaller infarctions on MRI and less neurological deficits at 3 months after stroke.

Patients entering the study will be investigated by transcranial Doppler ultrasound in case they have sufficient temporal bone windows for insonation and no stenosis or occlusions of major brain supplying arteries by the time of investigation that disturb the intracerebral blood flow.

All intracranial arteries will be assessed before treatment, after treatment and on day 8 after the insult.

Screen shots will be taken and will be analysed by dynamic vascular ultrasound (DVA), a new software algorithm developed by NHSi, to investigate microcirculatory information from the flow spectra of the major intracranial arteries.

The data from this post-hoc analysis are compared with the data of the polysomnography and with treatment.

Primary hypothesis in this substudy is that DVA reliably identifies patients with sleep apnea on days one and four after stroke. Secondary hypothesis is that DVA can distinguish between treated patients and controls.

Not Provided
Phase 1
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Brain Infarction
  • Device: non-invasive continuous positive airway pressure ventilation
  • Device: CPAP-treatment
    night time CPAP-mask ventilation
  • Experimental: A
    treatment with three nights of CPAP ventilation starting the first night of admission
    • Device: non-invasive continuous positive airway pressure ventilation
    • Device: CPAP-treatment
  • No Intervention: B
    usual Stroke Unit care
    Intervention: Device: CPAP-treatment

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Same as current
April 2008
January 2008   (Final data collection date for primary outcome measure)

Inclusion criteria:

  • AGE 18-85 years,
  • NIH-SS 2-20 points,
  • NIH-SS subitem 1a <=1.

Exclusion criteria:

  • Modified Rankin Scale Score >=2 on admission
  • primary intubation,
  • Congestive heart failure (NYHA >=3),
  • respiratory insufficiency
  • recurrent vomiting
  • absence of gag reflex,
  • participation in another RCT

for the ultrasound sub-study

  • absence of temporal bone window for insonation
  • stenosis or occlusion of major brain supplying arteries interfering with normal blood flow
Sexes Eligible for Study: All
18 Years to 85 Years   (Adult, Older Adult)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Dr. M. Ritter, University_Hospital_Muenster
University Hospital Muenster
  • New Health Sciences, Inc.
  • Rubel GmbH, Heiligenhaus, Germany
Principal Investigator: Darius G Nabavi, MD University Hospital Muenster
University Hospital Muenster
April 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP